Company news: J&J, Skyline, Medtronic and Salient

Share this article:

The Johnson & Johnson pharmaceutical R&D division of Janssen Pharmaceutica has signed a research agreement with Skyline Diagnostics, a Netherlands-based biotech company focusing on the development and marketing of gene signature-based diagnostic assays. Skyline will be working with Janssen to generate and analyze diagnostic information related to the use of an undisclosed, marketed compound, using the company's proprietary knowledge and technologies in the area of genetic profiling and bioinformatics. Under the terms of the agreement, Skyline will be receiving R&D funding and may receive payments on the achievement of certain research milestones.

 

Medtronic has announced that it has entered into a definitive agreement to acquire Salient Surgical Technologies, Inc., a global medical technology company that develops and markets advanced energy devices used in surgical procedures – including orthopaedic surgery, spine, open abdominal and thoracic procedures – in a transaction that will amount to $525 million. Medtronic had previously invested in Salient and currently holds an ownership stake in the company. The acquisition is subject to governmental and regulatory review in the U.S. and several countries. Until the transaction is completed, the companies will continue to operate as separate entities.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.